FS Reports最新文献

{"title":"Real-world use of an artificial intelligence–powered clinical decision support tool for ovarian stimulation","authors":"Cameron J. Bixby D.O. ,&nbsp;Bradley Miller M.D.","doi":"10.1016/j.xfre.2025.01.015","DOIUrl":"10.1016/j.xfre.2025.01.015","url":null,"abstract":"<div><h3>Objective</h3><div>To understand how treatment decisions and patient outcomes change with physician utilization of artificial intelligence (AI) to help determine follicle-stimulating hormone (FSH) starting dose and trigger injection timing during ovarian stimulation.</div></div><div><h3>Design</h3><div>Retrospective cohort study with historical controls.</div></div><div><h3>Subjects</h3><div>Patients undergoing ovarian stimulation by multiple physicians at one in vitro fertilization clinic in the United States.</div></div><div><h3>Exposure</h3><div>A total of 292 patients were treated between December 2022 and December 2023 with adjunctive clinician use of AI to help select starting dose of FSH and timing of the trigger injection. These were matched to 292 historical control patients treated between May 2019 and May 2022 by the same physicians without AI.</div></div><div><h3>Main Outcome Measures</h3><div>The primary endpoints were the starting FSH dose, total FSH dose, and number of metaphase II (MII) oocytes retrieved at the end of stimulation.</div></div><div><h3>Results</h3><div>The use of AI did not introduce any adverse events. After patient matching, there were no statistically significant differences in age, body mass index, antimüllerian hormone, or antral follicle count between the treatment and control groups. Comparing the treatment arm with the control arm, the average number of MII oocytes was 11.17 vs. 11.25, the average starting FSH dose was 397.09 IU vs. 443.84 IU, and the average total FSH dose was 4,181.77 IU vs. 4,654.71 IU.</div></div><div><h3>Conclusion</h3><div>Physician use of AI helped significantly reduce the starting and total FSH doses prescribed to patients without adversely affecting MII outcomes, indicating the potential use of AI in lowering in vitro fertilization costs to patients.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 2","pages":"Pages 140-146"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144312836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the gap: understanding racial disparities in polycystic ovary syndrome fertility treatment success","authors":"Amanda J. Adeleye M.D.","doi":"10.1016/j.xfre.2025.05.006","DOIUrl":"10.1016/j.xfre.2025.05.006","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 2","pages":"Page 176"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144312852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medical crowdfunding for cancer patients seeking fertility treatments: a cross-sectional analysis","authors":"Robyn A. Frankel M.D. ,&nbsp;Victoria Timmel M.D. ,&nbsp;Alexandra Peyser M.D. ,&nbsp;Baruch Abittan M.D. ,&nbsp;Christine Mullin M.D. ,&nbsp;Randi H. Goldman M.D.","doi":"10.1016/j.xfre.2025.01.016","DOIUrl":"10.1016/j.xfre.2025.01.016","url":null,"abstract":"<div><h3>Objective</h3><div>To explore the use of crowdfunding among patients with cancer seeking funding to offset the cost of fertility treatments.</div></div><div><h3>Design</h3><div>Cross-sectional analysis of campaigns initiated on a single popular crowdfunding website, GoFundMe, for the purpose of subsidizing fertility treatments in patients with cancer from April to May 2022.</div></div><div><h3>Subjects</h3><div>Patients utilizing crowdfunding campaigns to subsidize fertility treatments for either themselves or a partner with a cancer diagnosis. Campaigns unrelated to both cancer and fertility treatment coverage were excluded.</div></div><div><h3>Exposure</h3><div>Not applicable.</div></div><div><h3>Main Outcome Measures</h3><div>Dollar amount requested; amount and percent of goal obtained; top donation amount; number of donors or comments; geographic location; and cancer diagnosis. Chi-squared analyses and ANOVA statistics were used to characterize prevalence of geographic locations represented and differences in amount of financial support, respectively. A <em>P</em>&lt;.05 was considered statistically significant.</div></div><div><h3>Results</h3><div>A total of 1,195 campaigns were collected, spanning all regions of the United States and reflecting 23 different cancer diagnoses. The majority of campaigns resulted from breast (36.0%), lymphoma (10.6%), ovarian (7.1%), testicular (6.0%), or cervical (5.4%) cancer diagnoses. The average amount of funding requested across all campaigns was $31,390, with an average of $12,317 raised per campaign. More campaigns were initiated in Southern and Western regions of the United States compared with Northeastern and Midwestern (<em>P</em>&lt;.001). However, Northeastern campaigns raised more money (<em>P</em>=.001), came closer to reaching their goals (<em>P</em>=.03), and gained more social support, as evidenced by number of donors (<em>P</em>&lt;.001) and comments (<em>P</em>=.04). No statistically significant differences in financial or social outcomes were noted among campaigns when stratified by cancer type.</div></div><div><h3>Conclusion</h3><div>Patients with cancer who desire or require fertility treatments often face tremendous financial and social difficulties. Our results suggest a higher financial burden on patients with cancer in Southern and Western states, despite being less likely to reach financial goals or obtain as much social support as Northeastern counterparts. Overall, the majority of campaigns did not meet their financial goals.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 2","pages":"Pages 193-198"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144312989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To dose or to let artificial intelligence dose: that is the question!","authors":"Eduardo Hariton M.D., M.B.A. ,&nbsp;Salomon Edery","doi":"10.1016/j.xfre.2025.04.006","DOIUrl":"10.1016/j.xfre.2025.04.006","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 2","pages":"Pages 147-148"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144313020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Let’s stop equivocating: there is almost no reason to remove an endometrioma prior to fertility treatment, and there is every reason to offer fertility preservation prior to removing an endometrioma if removal is necessary","authors":"Richard J. Paulson M.D., M.S.","doi":"10.1016/j.xfre.2025.05.001","DOIUrl":"10.1016/j.xfre.2025.05.001","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 2","pages":"Pages 105-106"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144312837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Observational cohort study exploring MediEmo smartphone application use, live birth, and in vitro fertilization treatment return rates","authors":"Isla F. Robertson D.M. ,&nbsp;China R. Harrison Ph.D. ,&nbsp;Richard D. Morey Ph.D. ,&nbsp;Jacky Boivin Ph.D. ,&nbsp;Ying Cheong D.M.","doi":"10.1016/j.xfre.2025.04.003","DOIUrl":"10.1016/j.xfre.2025.04.003","url":null,"abstract":"<div><h3>Objective</h3><div>To explore the associations between the use of the MediEmo smartphone application and in vitro fertilization (IVF) live birth and treatment return rates.</div></div><div><h3>Design</h3><div>A 3-year observational cohort study</div></div><div><h3>Subjects</h3><div>Patients undergoing IVF were classified as users if they used the medication or emotion features of the MediEmo. Patients who did not use the two key features or declined to use the application were classified as nonusers.</div></div><div><h3>Exposure</h3><div>The use of the MediEmo smartphone application.</div></div><div><h3>Main outcome measures</h3><div>Outcomes of interest were the rate of live birth per fresh index cycle, live birth per complete cycle, and treatment return for a stimulated cycle of treatment within 12 months of the unsuccessful stimulated index cycle.</div></div><div><h3>Results</h3><div>A total of 1,081 patients were eligible to use the MediEmo application, 863 were categorized as users and 218 as nonusers. MediEmo use was associated with a higher live birth rate per index cycle than nonusers (27.81% [n = 240/863] vs. 19.26% [n = 42/218], respectively, OR, 1.248; 95% CI, 1.041–1.509) and treatment return rate compared with nonusers (46.00% [n = 169/363] vs. 31.37% [n = 32/102], respectively, OR, 1.339; 95% CI, 1.092–1.656). It was not associated with the live birth rate per complete cycle.</div></div><div><h3>Conclusion</h3><div>The observed positive association between MediEmo use and live birth and treatment return rates suggests benefits to patients and clinics. Further research and replication using a randomized controlled trial design are warranted, as is investment in the development of digital tools for use during IVF treatment.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 2","pages":"Pages 159-165"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144312849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of human chorionic gonadotropin hormone in restoring spermatogenesis in men using non-prescribed androgens: a retrospective analysis of real-world data","authors":"Diederik L. Smit M.D., Ph.D. ,&nbsp;Tijs Verdegaal M.D. ,&nbsp;Peter Bond M.Sc.","doi":"10.1016/j.xfre.2025.03.001","DOIUrl":"10.1016/j.xfre.2025.03.001","url":null,"abstract":"<div><h3>Objective</h3><div>To study the efficacy of human chorionic gonadotropin (hCG) in restoring spermatogenesis in men using non-prescribed androgens who are unwilling to discontinue their use.</div></div><div><h3>Design</h3><div>Retrospective analysis.</div></div><div><h3>Patients</h3><div>Nineteen men attending a harm reduction clinic in the Netherlands from April 2023 to July 2024, who had been using androgens for at least three months and were treated with hCG without ceasing androgen use.</div></div><div><h3>Exposure</h3><div>Continuous use of non-prescribed androgens and hCG therapy administered as part of a harm reduction strategy.</div></div><div><h3>Main Outcome Measures</h3><div>Change in total sperm count (TSC) and total motile sperm counts (TMSC) from baseline to after three to six months of hCG treatment.</div></div><div><h3>Results</h3><div>The mean TSC increased significantly from 18.0 million to 146.9 million after hCG treatment and TMSC increased from 1.1 million at baseline to 66.9 million post-treatment. The number of men with a normal TMSC increased from 5% to 58%. No statistically significant predictors of TSC change were identified through regression analysis.</div></div><div><h3>Conclusion</h3><div>Human chorionic gonadotropin appears to be effective in improving spermatogenesis in the majority of men who continue non-prescribed androgen use, whereas some men remain oligospermic or azoospermic. These findings support the cautious inclusion of hCG in harm reduction strategies, while emphasizing the need for further research and individualized counseling.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 2","pages":"Pages 120-126"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144312997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uterine fixation: advancing a multidisciplinary strategy for fertility preservation","authors":"Ariella Yazdani M.D. ,&nbsp;Mindy S. Christianson M.D., M.B.A.","doi":"10.1016/j.xfre.2025.04.004","DOIUrl":"10.1016/j.xfre.2025.04.004","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 2","pages":"Pages 225-226"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144312996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does time-lapse make the grade?","authors":"Sonali Gupta M.D.,&nbsp;Sangita K. Jindal Ph.D., H.C.L.D.","doi":"10.1016/j.xfre.2025.05.005","DOIUrl":"10.1016/j.xfre.2025.05.005","url":null,"abstract":"","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 2","pages":"Page 158"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144312848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ex vivo oocyte retrieval for fertility preservation in an adolescent patient with recurrent ovarian dysgerminoma: a case report and review of the literature","authors":"Addison W. Alley M.D. ,&nbsp;Leah J. Cooper M.D., M.S. ∗ ,&nbsp;Meredith A. Humphreys M.D. †,‡ ,&nbsp;Benjamin R. Emery M.Phil. ,&nbsp;Kenneth I. Aston Ph.D. ,&nbsp;Zachary J. Kastenberg M.D. ,&nbsp;Matthew X. Luo M.D. ,&nbsp;Katherine G. Hayes M.D. ,&nbsp;Douglas Fair M.D., M.S. ,&nbsp;Casey Mehrhoff D.O., M.S. ,&nbsp;Joseph M. Letourneau M.D. ,&nbsp;Krista J. Childress M.D.","doi":"10.1016/j.xfre.2025.01.017","DOIUrl":"10.1016/j.xfre.2025.01.017","url":null,"abstract":"<div><h3>Objective</h3><div>To describe fertility preservation via ex vivo oocyte retrieval for an adolescent patient undergoing oophorectomy for recurrent ovarian dysgerminoma and to review the available literature regarding this technique.</div></div><div><h3>Design</h3><div>Case report and literature review.</div></div><div><h3>Subjects</h3><div>A 17-year-old female with a medical history of right ovarian dysgerminoma treated with oophorectomy 3 years prior, who presented with a retroperitoneal mass noted during surveillance. Biopsy of the mass and remaining ovary confirmed recurrent stage III ovarian dysgerminoma. The patient desired fertility preservation. Ovarian tissue cryopreservation and traditional transvaginal oocyte retrieval were contraindicated because of the ovarian malignancy.</div></div><div><h3>Exposure</h3><div>The patient underwent controlled ovarian hyperstimulation with gonadotropins followed by laparotomy and left salpingo-oophorectomy 36 hours after ovulation trigger. An ex vivo retrieval of oocytes was performed under both direct visualization and ultrasound guidance in the operating room after excision of the ovary and isolated using a “mobile IVF” setup.</div></div><div><h3>Main Outcome Measure(s)</h3><div>Number of meiosis II oocytes cryopreserved.</div></div><div><h3>Results</h3><div>A total of 12 meiosis II oocytes were retrieved from the ovary and were successfully cryopreserved. The patient tolerated the procedure well and has since completed chemotherapy.</div></div><div><h3>Conclusion</h3><div>The combination of controlled ovarian hyperstimulation followed by ex vivo oocyte retrieval provides select patients with an opportunity for fertility preservation that may have otherwise faced a complete loss of fertility. In this case, the patient was able to preserve oocytes without jeopardizing her health status or delaying cancer therapy.</div></div>","PeriodicalId":34409,"journal":{"name":"FS Reports","volume":"6 2","pages":"Pages 208-215"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144312993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}